Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer

详细信息    查看全文

• 作者：Jin-Yan Lv ; Tai-Yuan Hu ; Ruo-Yu Wang ; Jin-Ming Zhu…
• 关键词：Colon cancer ; Angiogenesis ; Micrangium ; Endostatin ; Cyclophosphamide
• 刊名：World Journal of Surgical Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：14
• 期：1
• 全文大小：1,561 KB
• 参考文献：1.Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5:63.PubMed PubMedCentral CrossRef
  2.Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–8.PubMed CrossRef
  3.Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24.PubMed CrossRef
  4.Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005;65(23):11044–50.PubMed CrossRef
  5.O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.PubMed CrossRef
  6.Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001;7(11):3366–74.PubMed
  7.Eder Jr JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20(18):3772–84.PubMed CrossRef
  8.Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20(18):3804–14.PubMed CrossRef
  9.Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006;24(22):3555–61.PubMed CrossRef
  10.Sun L, Ye HY, Zhang YH, Guan YS, Wu H. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol. 2007;13(45):6115–8.PubMed PubMedCentral CrossRef
  11.Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, et al. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res. 2003;9(12):4619–26.PubMed
  12.Roy Choudhury S, Karmakar S, Banik NL, Ray SK. Targeting angiogenesis for controlling neuroblastoma. J Oncol. 2012;2012:782020.PubMed PubMedCentral CrossRef
  13.Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12):3670–84.PubMed PubMedCentral CrossRef
  14.Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27.PubMed CrossRef
  15.Qiao L, Wong BC. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009;30(12):1979–86.PubMed CrossRef
  16.Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, et al. Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69(2):573–82.PubMed PubMedCentral CrossRef
  17.Lai EC. Notch signaling: control of cell communication and cell fate. Development. 2004;131(5):965–73.PubMed CrossRef
  18.Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90(2):281–91.PubMed CrossRef
  19.Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Curr Mol Med. 2006;6(3):275–89.PubMed CrossRef
  20.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–5.PubMed CrossRef
  21.Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000;6(7):2751–8.PubMed
  22.Saphir A. Angiogenesis: the unifying concept in cancer? J Natl Cancer Inst. 1997;89(22):1658–9.PubMed
  23.Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol. 2000;34(2):89–110.PubMed CrossRef
  24.Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res. 1998;152:341–52.PubMed CrossRef
  25.Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med. 1975;141(2):427–39.PubMed CrossRef
  26.Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143(2):401–9.PubMed PubMedCentral
  27.O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994;59:471–82.PubMed CrossRef
  28.Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol. 1998;79(5):255–65.PubMed PubMedCentral CrossRef
  29.Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55(18):3964–8.PubMed
  30.Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28(6B):865–70.
  31.Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A. 2001;98(10):5643–8.PubMed PubMedCentral CrossRef
  32.Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, et al. Colorectal cancer: mutations in a signaling pathway. Nature. 2005;436(7052):792.PubMed CrossRef
  33.Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer. 2006;119(9):2071–7.PubMed CrossRef
  34.Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051–7.PubMed CrossRef
  35.Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67(23):11244–53.PubMed CrossRef
  36.O’Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2(6):689–92.PubMed CrossRef
  37.Boehm T, O’Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Zinc- binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun. 1998;252(1):190–4.PubMed CrossRef
  38.Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006;349(3):1073–8.PubMed CrossRef
  39.Prokopiou EM, Ryder SA, Walsh JJ. Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis. 2013;16(3):503–24.PubMed CrossRef
  40.Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62(10):2731–5.PubMed
  41.Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, et al. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014;74(12):3282–93.PubMed PubMedCentral CrossRef
  42.Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032–7.PubMed CrossRef
  43.Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol. 2013;19(1):42–8.PubMed PubMedCentral CrossRef
  44.Ren Z, Wang Y, Jiang W, Dai W, Jiang Y. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models. PLoS One. 2014;9(9):e107823.PubMed PubMedCentral CrossRef
  
• 作者单位：Jin-Yan Lv (1)
  Tai-Yuan Hu (2)
  Ruo-Yu Wang (1)
  Jin-Ming Zhu (1)
  Gang Wang (1)
  
  1. Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Jie Fang Street,Zhongshan District, Dalian, Liaoning, 116001, Peoples’ Republic of China
  2. Library, Liaoning University of International Business and Economics, Dalian, Liaoning, 116001, Peoples’ Republic of China
  
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819

文摘

Background The invasion of colon cancer is associated with the tumor angiogenesis. Endostatin is an important anti-angiogenic agent, and the additive effect of endostatin with a chemotherapeutic agent, cyclophosphamide, on micrangium has not been established.